CBD relieves nerve pain in mice partly through the opioid system
CBD produced pain relief in mice with nerve injury, and this effect was partially reversed by blocking mu and delta opioid receptors in the paw, revealing a peripheral opioid mechanism.
Quick Facts
What This Study Found
CBD at 20 mg/kg produced significant antinociception in mice with sciatic nerve injury. Naloxone (a general opioid blocker) reversed this effect. Selective mu (CTOP) and delta (naltrindole) opioid receptor antagonists partially reversed CBD analgesia, but the kappa antagonist (norBNI) did not.
Key Numbers
CBD at 20 mg/kg produced antinociception. Bestatin (400 microg/paw), an aminopeptidase inhibitor, potentiated the effect of a subtherapeutic CBD dose (2 mg/kg). Naloxone (50 microg/paw) reversed CBD analgesia. CTOP (mu antagonist) and naltrindole (delta antagonist) partially reversed the effect; norBNI (kappa antagonist) did not.
How They Did This
Male Swiss mice underwent sciatic nerve constriction injury to model neuropathic pain. Nociceptive threshold was measured using a mechanical paw pressure test. CBD was given systemically at 20 mg/kg, and various opioid receptor antagonists were injected locally into the paw to test which receptor subtypes were involved.
Why This Research Matters
CBD is widely discussed as a pain treatment, but its mechanisms remain poorly understood. This study identifies a specific pathway: CBD appears to activate peripheral opioid receptors (mu and delta types) as part of how it reduces nerve pain, which could help optimize future pain therapies.
The Bigger Picture
The finding that CBD engages the peripheral opioid system without being an opioid itself is significant. If CBD can activate endogenous opioid pathways without the addiction and respiratory depression risks of direct opioids, it could represent a safer approach to pain management. The potentiation by bestatin suggests CBD may work by enhancing the body's own opioid peptides.
What This Study Doesn't Tell Us
This is a mouse study using a surgical nerve injury model. Only male mice were tested. The doses and routes of administration may not translate directly to humans. The study does not clarify whether CBD acts directly on opioid receptors or triggers endogenous opioid release.
Questions This Raises
- ?Does CBD trigger release of endogenous opioid peptides, or does it interact with opioid receptors through another mechanism?
- ?Would this peripheral opioid pathway be relevant in human neuropathic pain?
- ?Could CBD enhance the effects of low-dose opioid therapy?
Trust & Context
- Key Stat:
- CBD analgesia was reversed by blocking mu and delta opioid receptors but not kappa receptors
- Evidence Grade:
- Single animal study in male mice using a nerve injury model, with pharmacological evidence for a specific mechanism.
- Study Age:
- Published in 2025.
- Original Title:
- Cannabidiol engages the peripheral endogenous opioid system to produce analgesia in neuropathic mice.
- Published In:
- Neuroscience letters, 868, 138393 (2025)
- Authors:
- de Almeida, Douglas Lamounier, Pinto Barra, Walace Cássio, Mendes Ferreira, Renata Cristina, Fonseca, Flávia Cristina, Dias Machado, Daniel Portela, Aguiar, Danielle Diniz, Guimaraes, Francisco Silveira, Gama Duarte, Igor Dimitri, Lima Romero, Thiago Roberto
- Database ID:
- RTHC-06309
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does this mean CBD is an opioid?
No. CBD is not an opioid, but this study found it appears to activate the body's own opioid pathways as part of its pain-relieving mechanism. This is different from drugs like morphine that directly bind opioid receptors.
Which opioid receptors were involved?
Mu and delta opioid receptors in the peripheral nervous system (tested in the paw) were involved. Kappa opioid receptors were not part of CBD's analgesic mechanism in this model.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06309APA
de Almeida, Douglas Lamounier; Pinto Barra, Walace Cássio; Mendes Ferreira, Renata Cristina; Fonseca, Flávia Cristina; Dias Machado, Daniel Portela; Aguiar, Danielle Diniz; Guimaraes, Francisco Silveira; Gama Duarte, Igor Dimitri; Lima Romero, Thiago Roberto. (2025). Cannabidiol engages the peripheral endogenous opioid system to produce analgesia in neuropathic mice.. Neuroscience letters, 868, 138393. https://doi.org/10.1016/j.neulet.2025.138393
MLA
de Almeida, Douglas Lamounier, et al. "Cannabidiol engages the peripheral endogenous opioid system to produce analgesia in neuropathic mice.." Neuroscience letters, 2025. https://doi.org/10.1016/j.neulet.2025.138393
RethinkTHC
RethinkTHC Research Database. "Cannabidiol engages the peripheral endogenous opioid system ..." RTHC-06309. Retrieved from https://rethinkthc.com/research/de-2025-cannabidiol-engages-the-peripheral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.